基于CYP2C19基因指导抗血小板治疗对不同民族缺血性卒中患者的临床疗效研究

doi:10.3969/j.issn.1673-5765.2024.10.002

摘要/Abstract

摘要： 目的分析不同民族缺血性卒中患者对基于快速细胞色素P450酶家族2亚家族C成员19 （cytochrome P450 family 2 subfamily C member 19，CYP2C19）基因检测指导抗血小板治疗方案的反应差异。
方法前瞻性连续纳入2023年1—7月在南宁市第三人民医院住院治疗的汉族（对照组）和壮族（试验组）非心源性轻型缺血性卒中患者。所有患者在CYP2C19基因检测结果指导下进行抗血小板治疗：对于基因表型为氯吡格雷快代谢的患者，抗血小板药物选择硫酸氢氯吡格雷；对于中间代谢或慢代谢的患者，抗血小板药物选择阿司匹林肠溶片或替格瑞洛片。随访90 d，记录mRS评分、日常生活能力量表（activity of daily living scale，ADL）评分、NIHSS评分以及90 d缺血性卒中累积复发率。
结果共纳入1036例缺血性卒中患者，对照组743例，CYP2C19基因检测结果显示，氯吡格雷快代谢、中间代谢、慢代谢型患者分别为299例（40.24%）、345例（46.43%）和99例（13.32%）。试验组293例，氯吡格雷快代谢、中间代谢、慢代谢型患者分别为107例（36.52%）、161例（54.95%）和25例（8.53%）。两组不同CYP2C19基因表型的比例差异无统计学意义。随访90 d，两组间的mRS评分、ADL评分、NIHSS评分差异无统计学意义。对照组和试验组的90 d缺血性卒中累积复发率分别为5.52%（41/743）和5.12%（15/293），差异无统计学意义。
结论基于CYP2C19基因检测指导的抗血小板治疗在汉族和壮族的缺血性卒中患者人群中，预防缺血性卒中复发的效果相似。

文章导读： 汉族和壮族的缺血性卒中患者在CYP2C19基因的代谢表型上主要表现为中间代谢型，这意味着两者在药物代谢方面有相似的特征。基于CYP2C19基因检测指导的抗血小板治疗对汉族和壮族的患者都是有效的，且效果相似。

关键词: 缺血性卒中; 抗血小板治疗; 细胞色素P450酶家族2亚家族C成员19; 汉族; 壮族

Abstract: Objective To analyze the difference in response of antiplatelet therapy guided by cytochrome P450 family 2 subfamily C member 19 (CYP2C19) gene detection in ischemic stroke patients of different ethnic groups.
Methods The prospective study consecutively included Han (the control group) and Zhuang (the experimental group) patients with non-cardiogenic mild ischemic stroke who were hospitalized for treatment at the Third People’s Hospital of Nanning from January to July 2023. All patients were administered antiplatelet therapy, with the choice of medication guided by CYP2C19 gene detection results. Fast metabolizers were given clopidogrel bisulfate, while intermediate or slow metabolizers were given enteric-coated aspirin or ticagrelor. A follow-up period of 90 days was established to record the mRS scores, activity of daily living scale (ADL) scores, NIHSS scores, and the cumulative recurrence rates of ischemic stroke at 90 days.
Results A total of 1036 patients with ischemic stroke were included, with 743 in the control group. The results of the CYP2C19 gene detection showed that there were 299 (40.24%) fast metabolizers,
345 (46.43%) intermediate metabolizers, and 99 (13.32%) slow metabolizers of clopidogrel. In the experimental group, there were 293 patients, with 107 (36.52%) fast metabolizers, 161 (54.95%) intermediate metabolizers, and 25 (8.53%) slow metabolizers of clopidogrel. The differences in the proportion of different CYP2C19 genotypes between the two groups were not statistically significant. After a 90 days follow-up, there was no significant difference in mRS scores, ADL scores, and NIHSS scores between the two groups. The cumulative recurrence rates of ischemic stroke at 90 days for the control group and the experimental group were 5.52% (41/743) and 5.12% (15/293), respectively, with no statistically significant difference.
Conclusions Antiplatelet therapy guided by CYP2C19 gene detection has similar effects in preventing the recurrence of ischemic stroke in Han and Zhuang patients.

Key words: Ischemic stroke; Antiplatelet therapy; Cytochrome P450 family 2 subfamily C member 19; Han; Zhuang

中图分类号:

谢姚屹, 黄妍菊, 樊敏, 岑花桃, 李燕丽, 卢苗值, 陆柏安, 韦穰芳, 吴志武. 基于CYP2C19基因指导抗血小板治疗对不同民族缺血性卒中患者的临床疗效研究[J]. 中国卒中杂志, 2024, 19(10): 1119-1124.

XIE Yaoyi, HUANG Yanju, FAN Min, CEN Huatao, LI Yanli, LU Miaozhi, LU Boan, WEI Rangfang, WU Zhiwu. Study on the Clinical Efficacy of Antiplatelet Therapy Guided by CYP2C19 Gene Detection in Ischemic Stroke Patients of Different Ethnic Groups[J]. Chinese Journal of Stroke, 2024, 19(10): 1119-1124.

参考文献

[1] 张建东，武湘云，任慧玲，等. 急性缺血性脑卒中患者抗血小板药物反应性与血小板参数及凝血功能的关系[J]. 河北医药，2023，45（6）：876-878，882.
ZHANG J D，WU X Y，REN H L，et al. Correlation between drug on platelet reactivity with platelet parameters and coagulation function in patients with acute ischemic stroke[J]. Hebei Medical Journal，2023，45（6）：876-878，882.
[2] MCDERMOTT J H，LEACH M，SEN D，et al. The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack[J]. Expert Rev Clin Pharmacol，2022，15（7）：811-825.
[3] 刘苗苗，王勃，韩东建，等. CYP2C19基因检测在冠心病患者PCI后抗血小板药物治疗中的指导价值[J]. 实用心脑肺血管病杂志，2023，31（4）：14-19.
LIU M M，WANG B，HAN D J，et al. Guiding value of CYP2C19 gene testing in antiplatelet drug therapy in patients with coronary heart disease after PCI[J]. Pract J Cardiac Cereb Pneum Vasc Dis，2023，31（4）：14-19.
[4] CHANG R，ZHOU W Q，YE Y，et al. Relationship between CYP2C19 polymorphism and clopidogrel resistance in patients with coronary heart disease and ischemic stroke in China[J/OL]. Genet Res，2022，2022（1）：1-11.
[5] NGUYEN A B，CAVALLARI L H，ROSSI J S，et al. Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy[J/OL]. Front Cardiovasc Med，2022，9：991646[2024-06-09]. https://doi.org/10.3389/fcvm.2022.991646.
[6] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组. 中国缺血性卒中和短暂性脑缺血发作二级预防指南2022[J]. 中华神经科杂志，2022，55（10）：1071-1110.
Chinese Society of Neurology，Chinese Stroke Society. Chinese guideline for the secondary prevention of ischemic stroke and transient ischemic attack 2022[J]. Chin J Neurol，2022，55（10）：1071-1110.
[7] WARIN R H. Cytochrome P450：genotype to phenotype[J]. Xenobiotica，2020，50（1）：9-18.
[8] AL-JENOBI F I，ALKHARFY K M，ALGHAMDI A M，et al. CYP2C19 genetic polymorphism in Saudi Arabians[J]. Basic Clin Pharmacol Toxicol，2013，112（1）：50-54.
[9] FAVELA-MENDOZA A F，MARTINEZ-CORTES G，HERNANDEZ-ZARAGOZA M，et al. Genetic variability of CYP2C19 in a Mexican population：contribution to the knowledge of the inheritance pattern of CYP2C19*17 to develop the ultrarapid metabolizer phenotype[J]. J Genet，2015，94（1）：3-7.
[10] ZHONG Z，HOU J，LI B，et al. Analysis of
CYP2C19 genetic polymorphism in a large ethnic Hakka population in Southern China[J/OL]. Med Sci Monit，2017，23：6186-6192[2024-06-09]. https://doi.org/10.12659/MSM.905337.
[11] JOHNSON J A. Pharmacogenetics in clinical practice：how far have we come and where are we going？[J]. Pharmacogenomics，2013，14（7）：835-843.
[12] FINKELSTEIN J，FRIEDMAN C，HRIPCSAK G，et al. Potential utility of precision medicine for older adults with polypharmacy：a case series study[J]. Pharmgenomics Pers Med，2016，9（1）：31-45.
[13] LAKIOTAKI K，KANTERAKIS A，KARTSAKI E，et al. Exploring public genomics data for population pharmacogenomics[J/OL]. PLoS One，2017，12（8）：e0182138[2024-06-09]. https://doi.org/10.1371/journal.pone.0182138.

[1]	曹黎明, 任力杰. 急性缺血性卒中诊疗技术的进展与展望[J]. 中国卒中杂志, 2024, 19(9): 983-989.
[2]	符鹏程, 曹黎明, 朱佳倩, 赵桂玉, 徐格林. 大动脉粥样硬化性缺血性卒中再灌注治疗的研究进展[J]. 中国卒中杂志, 2024, 19(9): 1004-1011.
[3]	张丽苹, 曹黎明, 肖楠, 廖雨琦, 池枫, 余艳妮, 任力杰. 纳米材料在缺血性卒中诊疗中的研究进展及挑战[J]. 中国卒中杂志, 2024, 19(9): 1012-1017.
[4]	王晓蕊, 骆嵩, 邹良玉, 屈洪党, 崔雪, 赵玉洁. 嗜酸性粒细胞与单核细胞比值预测急性缺血性卒中患者静脉溶栓预后的价值研究 [J]. 中国卒中杂志, 2024, 19(9): 1025-1033.
[5]	王铄, 余苹, 张宁, 王春雪. 2013—2023年缺血性卒中与睡眠相关性研究的文献计量学分析 [J]. 中国卒中杂志, 2024, 19(9): 1040-1047.
[6]	周宏宇, 李子孝, 王拥军. 基于影像组学预测大脑年龄与缺血性卒中的研究进展[J]. 中国卒中杂志, 2024, 19(9): 1066-1076.
[7]	阿娜古丽·阿不拉尼压孜, 吴晓欣, 李骄星, 李竹浩, 盛文利. 急性缺血性卒中磁敏感血管征影响因素及临床应用的研究进展[J]. 中国卒中杂志, 2024, 19(9): 1077-1085.
[8]	杨金波, 张聪. 高分辨率血管壁成像在缺血性卒中患者中的应用进展[J]. 中国卒中杂志, 2024, 19(9): 1086-1093.
[9]	吴春艳, 尹雅诗, 王广志, 岳奎涛. 急性缺血性卒中不同时间窗影像学评价及应用进展[J]. 中国卒中杂志, 2024, 19(9): 1094-1101.
[10]	张梦若, 徐守臣, 隋翠翠, 李玉奎, 王雪莉. 下肢康复机器人联合头针治疗对老年缺血性卒中患者步行效率和协调功能影响调查 [J]. 中国卒中杂志, 2024, 19(8): 902-908.
[11]	吴娱倩, 张玉梅, 臧大维, 范小伟, 王安心, 张晓丽, 孟霞. 上肢动作研究测试量表评定亚急性期缺血性卒中患者偏瘫侧上肢及手功能的信效度和敏感性研究 [J]. 中国卒中杂志, 2024, 19(8): 915-923.
[12]	莫秋红, 丁晓波, 李靓, 张岩波, 李伟荣. 基于可解释性机器学习模型的轻型缺血性卒中复发预测研究[J]. 中国卒中杂志, 2024, 19(8): 924-930.
[13]	逯丹, 陈玮琪, 王雅平, 段婉莹, 郭蕾, 王玲, 刘丽萍, 徐安定, 王拥军, 中国卒中学会脑保护圆桌会学术委员会. 缺血性卒中脑细胞保护科学声明——来自中国卒中学会的科学声明 [J]. 中国卒中杂志, 2024, 19(8): 938-955.
[14]	李光硕, 赵性泉. 《中国急性缺血性卒中诊治指南2023》解读[J]. 中国卒中杂志, 2024, 19(8): 956-961.
[15]	白磊鹏, 罗杰, 周思捷, 黄健辉, 梁铭钦, 赵庆顺. 肺叶楔形切除术后并发急性缺血性卒中行介入取栓治疗2例并文献回顾 [J]. 中国卒中杂志, 2024, 19(8): 962-966.